VivoSim (NASDAQ: VIVS) NAMkind™ Targets FDA’s New Testing Bar
October 6, 2026 The FDA’s push toward New Approach Methodologies (NAMs) could create an important opportunity for VivoSim Labs Inc. (NASDAQ: VIVS) and its NAMkind™ 3D human tissue platform, designed…
